On March 31, 2026, MiNK Therapeutics, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2025. The company reported a net loss of $2.6 million for Q4 2025, compared to a net loss of $2.5 million for the same period in 2024. For the full year, the net loss was $12.5 million, or $2.93 per share, compared to $10.8 million, or $2.86 per share, for 2024. Despite these losses, MiNK highlighted significant advancements in its clinical programs, particularly in the areas of immune restoration therapies. The company is advancing its Phase 2 trial for ARDS (acute respiratory distress syndrome) and has secured non-dilutive funding through collaborations and grants, including a NIH STTR grant for its graft-versus-host disease (GVHD) program. MiNK's CEO, Jennifer Buell, emphasized the strategic partnerships that have accelerated the company's progress and the potential of its iNKT cell therapies to address serious autoimmune and inflammatory conditions. The company is poised for a catalyst-rich 2026, with multiple clinical readouts expected in the coming year, including early data from the ARDS trial and advancements in its oncology programs. MiNK's focus on high-value immune restoration positions it well within the biopharmaceutical landscape, and the company is optimistic about its future prospects.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.